Phio Pharmaceuticals Corporation (PHIO) Quote

great day Capp

Fo sho!

cool Lover Nice

Good for a few bones, spuds.
'Buy' rating from H.C. Wainwright, alongside a price target of $14.

we are close on calls think I'm up one or 2 on you , I got DJT next call PHIO dam 14 target r u sure Lover?

nice call Lover

ya I knew u have been telling me for a while now lol

got some DJT figure it will hit 30 soon PHIO is the bomb

3 amigos me Capp and Lover know what to buy

looking good Capp

cool

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
Newsfile Corp.
Newsfile Corp
- Robert Infarinato named VP, Strategic Development

- Lisa Carson named as new VP, Finance and Administration

Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds. Recently, positive interim safety and efficacy results were reported in the on-going Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer. Clinical and preclinical data to date suggest promise for other potential applications across the INTASYL portfolio.

Mr. Robert Infarinato has been appointed to the role of VP, Strategic Development, effective June 9, 2025. He will be transitioning from his role as Chief Financial Officer to concentrate on directing strategic business development initiatives focusing on potential applications of the broader INTASYL portfolio. Concurrently, Ms. Lisa Carson, was appointed VP, Finance and Administration and will lead Phio's finance team.

Mr. Infarinato has over 30 years of finance and accounting leadership experience. He served as head of a consulting firm, advising on operational matters including funding and IPO process. Previous positions include serving as Chairman of the Board of Trustees for Abington Health and as executive Vice President and CFO of an international service company.

Ms. Carson joined Phio in May 2025 with more than 20 years of finance and accounting leadership experience. She most recently was VP, Finance and Controller at Prelude Therapeutics, where she supported the company's IPO and expansion. Ms. Carson also held leadership roles at TELA Bio and PhaseBio Pharmaceuticals.

"It is a great pleasure to announce the new positions of these two experienced professionals," said Robert Bitterman, Phio's CEO and President. "This strategic move underscores the company's commitment to gain greater awareness of the potential applications in our INTASYL siRNA portfolio."

I have always liked this baby!😍

Pretty 😍 

ok Capp thanks

I'm in too. You should take a look at $HSDT as a bounce play. Low float even with the recent offering.

Thanks !! Appreciate you!

Believe this one is going to go again. Just a heads up while folks are not looking. lol

PHIO showing some energy this morning.

I'LL go in with 2k shares y not PHIO

wowzer bowzer FEE FI FOE PHIO

$14.00 price target. Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Price Target | PHIO Stock News

https://www.gurufocus.com/news/2909672/phio-pharmaceuticals-phio-gains-buy-rating-with-promising-price-target-phio-stock-news

ok cool I need PLUG to come to bear fruit

$PHIO is one of my favorite biotech plays!😁

ya lover all good

OT: I just started buying PLUG and now messaged you on their thread—amazing 1/2 billion $ line of credit.

ya insane

OT: Did you read this huge PLUG release? Plug Power Closes $525 Million Secured Credit Facility with Yorkville Advisors
Plug to Hold First Quarter 2025 Earnings Call on May 12, 2025
SLINGERLANDS, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced the initial closing of its previously announced $525 million secured term loan facility with Yorkville Advisors. The initial tranche in an aggregate principal amount of $210 million was drawn and funded. Commensurate with establishing this facility, the company has retired $82.5 million in aggregate principal of the existing convertible debenture with Yorkville Advisors, which had approximately 55 million associated underlying shares given the conversion price, and therefore this refinancing has reduced potential dilution. The transaction enhances Plug’s liquidity position and provides the company with additional financial flexibility as it continues to scale its green hydrogen network and drive toward profitability.

“This financing provides meaningful capital to support Plug’s strategic priorities in 2025 and beyond,” said Andy Marsh, CEO of Plug. “We appreciate the confidence Yorkville has shown in our long-term vision and are pleased to have closed this deal under favorable terms for the company.”

Plug will provide further details during its upcoming first quarter 2025 earnings call.

Q1 2025 Earnings Conference Call Details:

Plug’s First Quarter 2025 results will be released on Monday, May 12, 2025.

Join the call

Time: 4:30 pm ET
Participant Dial-In: 877-407-9221 / +1 201-689-8597
Webcast: https://event.webcasts.com/starthere.jsp?ei=1718659&tp_key=e4fec597b7
A live webcast will be available on the Plug Investor Relations website at https://www.ir.plugpower.com, and a playback will be available online for a period of time following the call.

cool into PLUG i am watching

EXCELLENT! This cancer research shows much promise! ♥️ 😇

heavy in PLUG 100K

Here you go Spuds buddy = Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Newsfile Corp.
Newsfile Corp
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort
Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10th
Marlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (cSCC) treated in the third dose cohort. The third patient was reported as having a pathologic non-response (

PHIO...........................................p/m

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176074282

Lol

Color me crazy....again. 2.23 it's like it was talking to me with it's eyes. lol

See the % gains here, Spuds! We're pushing $3 :) The strength of the team is each individual member. The strength of each member is the team.😍♥️

I started to scan for something before leaving out and thought I'd just check my watchlist and this one was there. So lucky for that.
GLTU 81

PS: I had a 89 for a few years. Love that they already had a 6 spd at that time. That was something new for me back then.
I wasn't used to getting over 100mph and still have 2 gears left. 🤪

PHIO,nice grab! I should have bought it yesterday but I wanted 3 solder candles for confirmation of run continue not a pump and dump on no news,bought on the only dip in death hr,had many bids in(2.54 only filled)
Maybe news and a gap up to $10 tomorrow is going to be the hype,hope,fomo.
No shares showing up to short is promising,solid zb,it does hint big news coming if they won’t loan out their shares to short
Good skill to you bro!

Jumped into this one about 7:05 this morning @ 2.23 and had to run out.
Just added 2.87

PHIO going for nhod in death hr,moving freely on low vol,expect vol surges soon that increase,has gapped to $10 before so greed could be strong,also skin cancer cure for potential

bids filling,ZB/126%fee(no rebate)charting up,moving freely

Spending 150% of cash how much burn is going to be needed to finish phase 2 and phase 3 and get fda approvals and then distribution and a lot of other fees expenses and hopefully works if does hell yeah will be bought by another company imo but won't be for a long time and have to do more R&D. then the company technically will only have a paycheck.

"You bet your sweet bippy" 🥰

Nice move PHIO

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Newsfile Corp.
Newsfile Corp
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration

Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.

Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.

"We are impressed with the continuing safety profile of PH-762 having now progressed through the first 3 escalating doses," said Mary Spellman, MD, Phio's acting Chief Medical Officer.

Previously, seven patients diagnosed with cutaneous carcinomas were treated in dose cohorts 1 and 2. The second cohort enrolled a total of 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision) in the second cohort, two patients had a complete response (100% tumor clearance), and one patient had a partial response (90% clearance). All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.

"We are optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer," said Robert Bitterman, President and CEO of Phio Pharmaceuticals.

About Phio Pharmaceuticals Corp.

lol made nothing today ahh lost 200

LMFAO!🤣 and I always thought it was the other way around!🤑😋

i make a grand a day 5 days and then jack off